Company Description
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States.
The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Robert Bitterman |
Contact Details
Address: 11 Apex Drive, Suite 300A Marlborough, Massachusetts 01752 United States | |
| Phone | 508 767 3861 |
| Website | phiopharma.com |
Stock Details
| Ticker Symbol | PHIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533040 |
| CUSIP Number | 71880W303 |
| ISIN Number | US71880W4024 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert J. Bitterman | President, Chief Executive Officer and Chairman |
| Robert M. Infarinato CPA, Esq. | Chief Financial Officer and Principal Accounting Officer |
| Linda M. Mahoney | Senior Vice President of Development |
| Caitlin Kontulis | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 21, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jan 17, 2025 | SCHEDULE 13G | Filing |
| Jan 17, 2025 | 8-K | Current Report |
| Jan 17, 2025 | 424B5 | Filing |
| Jan 15, 2025 | 8-K | Current Report |
| Jan 15, 2025 | 424B5 | Filing |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 424B5 | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 7, 2025 | D | Notice of Exempt Offering of Securities |